Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Rimonabant

Stage Phase 3Stale

Sponsor Sanofi

Route oral

Class CB1

Mechanism selective cannabinoid CB1 receptor antagonist

Sources

registry, as of 2016-05-20Stale

https://clinicaltrials.gov/study/NCT00263042

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 18695. Conditions Cardiovascular Disease. The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the ri

ClinicalTrials.gov NCT00263042 protocol and results modules

registry, as of 2009-04-20Stale

https://clinicaltrials.gov/study/NCT00029861

Obese Patients With or Without Comorbidities (RIO-North America). Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 3045. Conditions Obesity; Weight Loss. To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities

ClinicalTrials.gov NCT00029861 protocol and results modules

registry, as of 2011-01-26Stale

https://clinicaltrials.gov/study/NCT00405808

Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 2666. Conditions Obesity. Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese pati

ClinicalTrials.gov NCT00405808 protocol and results modules

registry, as of 2009-04-20Stale

https://clinicaltrials.gov/study/NCT00386061

Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe). Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 1507. Conditions Obesity. The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. The main secondary objectives were to assess the effect of SR141716

ClinicalTrials.gov NCT00386061 protocol and results modules

registry, as of 2009-04-20Stale

https://clinicaltrials.gov/study/NCT00029848

Obese Patients With Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 1045. Conditions Obesity; Diabetes Mellitus, Non-Insulin-Dependent; Obesity in Diabetes. To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes

ClinicalTrials.gov NCT00029848 protocol and results modules

registry, as of 2009-04-20Stale

https://clinicaltrials.gov/study/NCT00029835

Obese Patients With Untreated Dyslipidemias. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 1033. Conditions Obesity; Dyslipidemia. To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

ClinicalTrials.gov NCT00029835 protocol and results modules

registry, as of 2009-07-20Stale

https://clinicaltrials.gov/study/NCT00434096

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS). Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 915. Conditions Obesity. The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks. Secondary objectives are: * To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL

ClinicalTrials.gov NCT00434096 protocol and results modules

registry, as of 2009-04-20Stale

https://clinicaltrials.gov/study/NCT00124332

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study). Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 839. Conditions Coronary Atherosclerosis. The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological th

ClinicalTrials.gov NCT00124332 protocol and results modules

registry, as of 2009-04-07Stale

https://clinicaltrials.gov/study/NCT00239967

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 803. Conditions Dyslipidemia; Obesity. The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600 kcal deficit per day) in abdominally obese patients w

ClinicalTrials.gov NCT00239967 protocol and results modules

registry, as of 2016-05-20Stale

https://clinicaltrials.gov/study/NCT00228176

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 661. Conditions Carotid Artery Plaque; Arteriosclerosis; Obesity; Metabolic Syndrome X. Objectives: * Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) * Secondary: To evaluate the safety and tolerability of the abo

ClinicalTrials.gov NCT00228176 protocol and results modules

publication, as of 2005-05-27Stale

https://pubmed.ncbi.nlm.nih.gov/15755787/

antagonist. To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant, a new selective cannabinoid receptor antagonist. Primary literature and review articles were obtained via a MEDLINE search (1966-November 2004) using the key terms obesity, smoking cessation, cannabinoid, rimonabant, SR 141716,

PMID 15755787

Studies

CRESCENDO

Registry NCT00263042

EudraCT 2005-002942-20

Phase Phase 3

Status Terminated

Enrollment 18695

Rimonabant

Regimen once daily

Comparator placebo

Population Cardiovascular Disease

Placebo

Regimen once daily

Population Cardiovascular Disease

Obese Patients With or Without Comorbidities (RIO-North America)

Registry NCT00029861

Phase Phase 3

Status Completed

Enrollment 3045

Registry arm not named

Population Obesity; Weight Loss

PRADO

Registry NCT00405808

Phase Phase 3

Status Terminated

Enrollment 2666

1

Regimen once daily

Comparator placebo

Population Obesity

2

Regimen once daily

Population Obesity

Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

Registry NCT00386061

Phase Phase 3

Status Completed

Enrollment 1507

Registry arm not named

Population Obesity

RIO-Diabetes

Registry NCT00029848

Phase Phase 3

Status Completed

Enrollment 1045

Registry arm not named

Population Obesity; Diabetes Mellitus, Non-Insulin-Dependent; Obesity in Diabetes

RIO-Lipids

Registry NCT00029835

Phase Phase 3

Status Completed

Enrollment 1033

Registry arm not named

Population Obesity; Dyslipidemia

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

Registry NCT00434096

Phase Phase 3

Status Terminated

Enrollment 915

1

Regimen once daily

Weeks 52

Comparator placebo

Population Obesity

2

Regimen once daily

Weeks 52

Population Obesity

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Registry NCT00124332

Phase Phase 3

Status Completed

Enrollment 839

Registry arm not named

Regimen once daily

Population Coronary Atherosclerosis

ADAGIO-lipids

Registry NCT00239967

Phase Phase 3

Status Completed

Enrollment 803

Registry arm not named

Regimen once daily

Population Dyslipidemia; Obesity

AUDITOR

Registry NCT00228176

EudraCT 2005-001612-49

Phase Phase 3

Status Terminated

Enrollment 661

Rimonabant

Regimen once daily

Comparator placebo

Population Carotid Artery Plaque; Arteriosclerosis; Obesity; Metabolic Syndrome X

Placebo

Regimen once daily

Population Carotid Artery Plaque; Arteriosclerosis; Obesity; Metabolic Syndrome X